HIV

This year, at the International Workshop on HIV Pediatrics and IAS our ODYSSEY and SMILE studies and EPIICAL will be presenting abstracts in various sessions.

On June 21-22, the International Workshop on Innovation in the delivery of HIV care will take place virtually. This is an important workshop highlighting the need for flexibility and innovation when it comes to caring for people living with HIV,

EPIICAL is proud to have presented four abstracts at the CROI conference this year, sharing updated information on viral decay and the immune response of children living with HIV who begin treatment early in life.

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections.

Penta is the coordinator for the newly funded EDCTP project – UNIVERSAL!  Later in the day, we will be speaking with partners at the official kick-off meeting.

This morning, at the 23rd International AIDS Conference, our collaborator Martina Penazzato provided a plenary speech on pediatric HIV. We met with her and asked for her thoughts on what urgent action we need to take to end AIDS in children.

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part,

With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs that the scientific community has made in the treatment of paediatric HIV. 

The Cascade of Care, more commonly known as the HIV care continuum, is a calculation of how many people in a specific population diagnosed with HIV are initially linked to care,

On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV.

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15^th September. 

Last Patient Last Visit (LPLV) completed for the Penta 17 Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (SMILE) trial.

The Penta sponsored trial,

Results from from the ongoing P1093 and ODYSSEY (PENTA20) studies, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir.

We are proud to announce that the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) was awarded a grant from the ViiV Global HIV and COVID-19 Emergency Fund to conduct research on the direct and indirect impact of COVID-19 on children and adolescents living with HIV across Europe and South Africa.

The 23^rd International AIDS Conference take virtually place from today to July 10^th. Attendants have the possibility to engage with the latest HIV science,

Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets for children of 4 weeks of age and older.

Join the 6th Workshop on Children and Adolescents HIV-exposed and Uninfected (HEU) at 3pm (CEST) on 1st July 2020.

The workshop is part of the pre-conference programme of the International AIDS virtual conference 2020.